Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McLachlan, R. S.
Right arrow Articles by Blume, W. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McLachlan, R. S.
Right arrow Articles by Blume, W. T.
NEUROLOGY 1996;47:925-928
© 1996 American Academy of Neurology

Treatment of Rasmussen's syndrome with ganciclovir

Richard S. McLachlan, MD, FRCP(C), Simon Levin, MD, FRCP(C) and Warren T. Blume, MD, FRCP(C)

From the Departments of Clinical Neurological Sciences and Pediatrics, University of Western Ontario, London, Ontario, Canada.
Received November 1, 1995. Accepted in final form January 17, 1996.
Address correspondence and reprint requests to Dr McLachlan, London Health Sciences Centre, London, Ontario, Canada, N6A 5A5.

Since cytomegalovirus (CMV) has been implicated in the pathogenesis of Rasmussen's syndrome, we treated four patients with ganciclovir, a potent anti-CMV drug. A 7-year-old girl with seizures escalating to 60/day over 3 months despite triple antiepileptic drug therapy became seizure-free 5 days after initiation of treatment with no recurrence at 1.5 years follow-up. Focal neurologic signs, cognitive function, and the EEG returned to normal. Two patients treated 34 and 72 months after disease onset in association with epilepsy surgery had a reduction in seizures and one had no response. CMV genome was detected in the brains of two of the three patients in whom it was assessed. The response to antiviral therapy supports a viral etiology for chronic encephalitis of Rasmussen. If the disease is suspected, treatment with ganciclovir should be considered as early as possible.

NEUROLOGY 1996;47: 925-928




This article has been cited by other articles:


Home page
 BrainHome page
C. G. Bien, T. Granata, C. Antozzi, J. H. Cross, O. Dulac, M. Kurthen, H. Lassmann, R. Mantegazza, J.-G. Villemure, R. Spreafico, et al.
Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: A European consensus statement
Brain, March 1, 2005; 128(3): 454 - 471.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
T. Granata, G. Gobbi, R. Spreafico, F. Vigevano, G. Capovilla, F. Ragona, E. Freri, L. Chiapparini, P. Bernasconi, L. Giordano, et al.
Rasmussen's encephalitis: Early characteristics allow diagnosis
Neurology, February 11, 2003; 60(3): 422 - 425.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. Villani, R. Spreafico, L. Farina, A.R. Giovagnoli, P. Bernasconi, T. Granata, and G. Avanzini
Positive response to immunomodulatory therapy in an adult patient with Rasmussen's encephalitis
Neurology, January 23, 2001; 56(2): 248 - 250.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
L. C. Gahring and S. W. Rogers
Autoimmunity to Glutamate Receptors in Rasmussen's Encephalitis: A Rare Finding or The Tip of an Iceberg?
Neuroscientist, September 1, 1998; 4(5): 373 - 379.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by AAN Enterprises, Inc.